Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories

PJ Bingley, AJK Williams, PG Colman, SA Gellert, G Eisenbarth, L Yu, LH Perdue, JE Hilner, C Nierras, B Akolkar, MW Steffes, [No Value] T1DGC

Research output: Contribution to journalArticle (Academic Journal)

20 Citations (Scopus)

Abstract

BACKGROUND: and PURPOSE: Three network laboratories measured antibodies to islet autoantigens. Antibodies to glutamic acid decarboxylase (GAD65 [GADA]) and the intracellular portion of protein tyrosine phosphatase (IA-2(ic) [IA-2A]) were measured by similar, but not identical, methods in samples from participants in the Type 1 Diabetes Genetics Consortium (T1DGC). METHODS: All laboratories used radiobinding assays to detect antibodies to in vitro transcribed and translated antigen, but with different local standards, calibrated against the World Health Organization (WHO) reference reagent. Using a common method to calculate WHO units/mL, we compared results reported on samples included in the Diabetes Autoantibody Standardization Program (DASP), and developed standard methods for reporting in WHO units/mL. We evaluated intra-assay and inter-assay coefficient of variation (CV) in blind duplicate samples and assay comparability in four DASP workshops. RESULTS: Values were linearly related in the three laboratories for both GADA and IA-2A, and intra-assay technical errors for values within the standard curve were below 13% for GADA and below 8.5% for IA-2A. Correlations in samples tested 1-2 years apart were >97%. Over the course of the study, internal CVs were 10-20% with one exception, and the laboratories concordantly called samples GADA or IA-2A positive or negative in 96.7% and 99.6% of duplicates within the standard curve. Despite acceptable CVs and general concordance in ranking samples, the laboratories differed markedly in absolute values for GADA and IA-2A reported in WHO units/mL in DASP over a large range of values. LIMITATIONS: With three laboratories using different assay methods (including calibrators), consistent values among them could not be attained. CONCLUSIONS: Modifications in the assays are needed to improve comparability of results expressed as WHO units/mL across laboratories. It will be essential to retain high intra- and inter-assay precision, sensitivity and specificity and to confirm the accuracy of harmonized methods.
Translated title of the contributionMeasurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories
Original languageEnglish
Pages (from-to)56 - 64
Number of pages9
JournalClinical Trials
Volume7
DOIs
Publication statusPublished - 2010

Fingerprint Dive into the research topics of 'Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories'. Together they form a unique fingerprint.

  • Cite this

    Bingley, PJ., Williams, AJK., Colman, PG., Gellert, SA., Eisenbarth, G., Yu, L., Perdue, LH., Hilner, JE., Nierras, C., Akolkar, B., Steffes, MW., & T1DGC, N. V. (2010). Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories. Clinical Trials, 7, 56 - 64. https://doi.org/10.1177/1740774510373496